MedTrace Logo

Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products

NCT03230825 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-08-08

No results posted yet for this study

Summary

We speculate that the use of combined oral contraceptives may be a possible solution to promote the management of retained pregnancy products versus expectant management. By withdrawing the pill, the endometrium is expected to shed in a synchronized fashion (estrogen and progestin withdrawal bleeding and may also shed the retained products of conception and avoid a surgical procedure with its related potential complications.

Conditions

  • Retained Products of Conception Post Abortion

Interventions

DRUG

Oral contraceptive

Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)

OTHER

Expectant management

No intervention and a follow up visit a wewk later

Sponsors & Collaborators

  • Meir Medical Center

    lead OTHER

Principal Investigators

  • Anat Hershko Klement, MD · Meir Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
54 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-30
Primary Completion
2018-09-30
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03230825 on ClinicalTrials.gov